Santen Sirolimus drug secures FDA orphan drug status – Pharmaceutical Business Review
Santen Sirolimus drug secures FDA orphan drug statusPharmaceutical Business ReviewThe US FDA has granted orphan drug status for Santen's sirolimus (DE-109, rapamycin) to treat chronic/refractory anterior non-infectious uveitis, non-infectious inter…